CR

Generational Equity Advises Alloyweld Inspection in its Sale to Acuren Inspection

Retrieved on: 
Friday, October 20, 2023

Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client Alloyweld Inspection to Acuren Inspection, Inc.

Key Points: 
  • Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client Alloyweld Inspection to Acuren Inspection, Inc.
  • Located in Bensenville and Elgin, Illinois, Alloyweld Inspection (Alloyweld) serves critical industries, including aerospace, electronics, medical devices, and forensics.
  • Alloyweld was one of the world’s first organizations to achieve National Aerospace & Defense Contractors Accreditation Program (NADCP) certification in CR and DR digital x-ray inspection.
  • Acuren shares many of the same values and is the perfect partner for the Alloyweld family,” said LePage.

Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise

Retrieved on: 
Monday, October 23, 2023

VANCOUVER, BC, Oct. 23, 2023 /PRNewswire/ -- USA News Group - Despite being a relatively rare form of cancer, pancreatic cancer remains one of the deadliest in the oncology field, the third leading cause of cancer death in the USA. Still not fully understood, pancreatic cancer's 5-year survival rate is currently only 12%. New analysis of data from the National Program of Cancer Registries database, covering around 65% of the US population, suggests that the incidence of pancreatic cancer among individuals younger than 55 years is increasing more rapidly than in those 55 years or older, and also more quickly in women than in men. As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder. Thankfully, within the biotech sector, there have been plenty of developments giving hope in the fight against pancreatic cancer, including those from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Eli Lilly and Company, Roche Holding AG (OTC:RHHBY), BioNTech SE (NASDAQ:BNTX), and even 23andMe Holding Co (NASDAQ:ME).

Key Points: 
  • As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder .
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • The BRCA1 and BRCA2 variants may also be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers.
  • "It's an important milestone that shows we're headed in the right direction – and this means so much to all those affected by pancreatic cancer."

Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise

Retrieved on: 
Monday, October 23, 2023

VANCOUVER, BC, Oct. 23, 2023 /PRNewswire/ -- USA News Group - Despite being a relatively rare form of cancer, pancreatic cancer remains one of the deadliest in the oncology field, the third leading cause of cancer death in the USA. Still not fully understood, pancreatic cancer's 5-year survival rate is currently only 12%. New analysis of data from the National Program of Cancer Registries database, covering around 65% of the US population, suggests that the incidence of pancreatic cancer among individuals younger than 55 years is increasing more rapidly than in those 55 years or older, and also more quickly in women than in men. As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder. Thankfully, within the biotech sector, there have been plenty of developments giving hope in the fight against pancreatic cancer, including those from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Eli Lilly and Company, Roche Holding AG (OTC:RHHBY), BioNTech SE (NASDAQ:BNTX), and even 23andMe Holding Co (NASDAQ:ME).

Key Points: 
  • As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder .
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • The BRCA1 and BRCA2 variants may also be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers.
  • "It's an important milestone that shows we're headed in the right direction – and this means so much to all those affected by pancreatic cancer."

SK chemicals, Storing Music in Circular Recycled Plastics

Retrieved on: 
Thursday, October 19, 2023

SEONGNAM, South Korea, Oct. 18, 2023 /PRNewswire/ -- SK chemicals supplies circular recycled materials to the global record market.

Key Points: 
  • SEONGNAM, South Korea, Oct. 18, 2023 /PRNewswire/ -- SK chemicals supplies circular recycled materials to the global record market.
  • SK chemicals (CEO Ahn Jae-hyun) announced on the 19th that it co-developed the "EcoRecord" LP made from 100% recycled materials with global record producer Sonopress.
  • Circular recycling is an exclusive chemical recycling technology of SK chemicals that breaks down discarded plastics through chemical reactions into raw material units and then uses these raw materials to produce recycled plastics.
  • SK chemicals is also considering signing a business agreement with local distributors and Sonopress to ensure a stable supply of circular recycled materials.

Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Followed by Opdivo Demonstrates Significant Survival Benefits for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in Phase 3 CheckMate -901 Trial

Retrieved on: 
Tuesday, October 17, 2023

At the 12- and 24-month landmark analyses, patients treated with upfront Opdivo plus chemotherapy experienced OS rates of 70.2% and 46.9%, respectively, compared to 62.7% and 40.7% with chemotherapy.

Key Points: 
  • At the 12- and 24-month landmark analyses, patients treated with upfront Opdivo plus chemotherapy experienced OS rates of 70.2% and 46.9%, respectively, compared to 62.7% and 40.7% with chemotherapy.
  • The landmark 12- and 24-month PFS rates were 34.2% and 23.5%, compared to 21.8% and 9.6% with chemotherapy.
  • The combination of Opdivo with cisplatin-based chemotherapy had a tolerable safety profile consistent with the known safety profiles of the individual components of the regimen.
  • “In patients with metastatic urothelial carcinoma, we often see poor durability of responses with chemotherapy alone in the first-line treatment setting.

Y-mAbs Announces Publication in Cancers

Retrieved on: 
Monday, October 16, 2023

“The publication in Cancers further validates the utilization of naxitamab early during the course of treatment for patients with high-risk neuroblastoma,” said Thomas Gad, Founder, President and Interim Chief Executive Officer.

Key Points: 
  • “The publication in Cancers further validates the utilization of naxitamab early during the course of treatment for patients with high-risk neuroblastoma,” said Thomas Gad, Founder, President and Interim Chief Executive Officer.
  • Cycles were administered 3-5 weeks apart and the primary endpoint was overall response rate (CR + partial response (“PR”)).
  • The HITS combination did not appear to exacerbate the rate nor the intensity of infusion-related toxicities of naxitamab when observed as a stand-alone treatment.
  • Researchers at Memorial Sloan Kettering Cancer Center (MSK) developed DANYELZA® (naxitamab-gqgk), which is exclusively licensed by MSK to Y-mAbs.

Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil

Retrieved on: 
Monday, October 16, 2023

As a result, Knight expects to launch Minjuvi® in Brazil in the second quarter of 2024.

Key Points: 
  • As a result, Knight expects to launch Minjuvi® in Brazil in the second quarter of 2024.
  • “We’re excited to continue to advance the approval of Minjuvi® in Brazil, a new treatment option for a current unmet need.
  • We look forward to launching Minjuvi® in Brazil and obtaining approval in other key markets in Latin America,” said Samira Sakhia, Knight Therapeutics President and CEO.
  • “Knight’s team is working diligently with physicians, key institutions and payors to ensure patients have access to Minjuvi®,” said Cristiane Coelho, Knight Therapeutics Brazil General Manager.

ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023

Retrieved on: 
Wednesday, October 18, 2023

“The positive safety profile, consistent with previous data in solid tumor patients, together with the promising clinical activity underscores the potential of ICT01 in hematological malignancies.

Key Points: 
  • “The positive safety profile, consistent with previous data in solid tumor patients, together with the promising clinical activity underscores the potential of ICT01 in hematological malignancies.
  • “We continue to generate highly encouraging clinical signals in both solid and hematological tumors.
  • The reported data did not reveal any dose-limiting toxicities and demonstrated a DCR of 30% among the 10 evaluable patients at week 8.
  • Based on these results, the company has started evaluating ICT01 in combination with Venetoclax/azacitidine in a Phase IIa expansion cohort in first-line AML patients.

Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment

Retrieved on: 
Wednesday, October 11, 2023

VANCOUVER, British Columbia, Oct. 11, 2023 /PRNewswire/ -- USA News Group - Researchers are becoming increasingly concerned with the rates of cancer on the rise among people under 50. A recent study found a nearly 80% global increase in the number of under-50s getting diagnosed with cancer from 1990 to 2019. And among the most worrying rise is in pancreatic cancer, which comes with extremely low survival rates. However, with strategies such as the "Cancer Moonshot," a $200M boost from a newly formed VC firm, and sustained efforts from the Pancreatic Cancer Action Network (PanCAN), a leading pancreatic cancer organization, which this year noted the 5-year survival rate is approximately 12%. Many new developments are currently underway from biotech firms searching for new treatments and methods of diagnosis, including those from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Genelux Corporation (NASDAQ: GNLX), Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), Pfizer Inc. (NYSE: PFE) and Seagen Inc. (NASDAQ: SGEN).

Key Points: 
  • And among the most worrying rise is in pancreatic cancer, which comes with extremely low survival rates.
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • Further survival follow up is required to inform our next steps in pancreatic cancer," said Roger Dansey, M.D., Chief Medical Officer at Seagen.
  • "We are continuing to advance the ongoing phase 2 trial of SEA-CD40 in melanoma and in non-small cell lung cancer."

Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment

Retrieved on: 
Wednesday, October 11, 2023

VANCOUVER, British Columbia, Oct. 11, 2023 /PRNewswire/ -- USA News Group - Researchers are becoming increasingly concerned with the rates of cancer on the rise among people under 50. A recent study found a nearly 80% global increase in the number of under-50s getting diagnosed with cancer from 1990 to 2019. And among the most worrying rise is in pancreatic cancer, which comes with extremely low survival rates. However, with strategies such as the "Cancer Moonshot," a $200M boost from a newly formed VC firm, and sustained efforts from the Pancreatic Cancer Action Network (PanCAN), a leading pancreatic cancer organization, which this year noted the 5-year survival rate is approximately 12%. Many new developments are currently underway from biotech firms searching for new treatments and methods of diagnosis, including those from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Genelux Corporation (NASDAQ: GNLX), Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), Pfizer Inc. (NYSE: PFE) and Seagen Inc. (NASDAQ: SGEN).

Key Points: 
  • And among the most worrying rise is in pancreatic cancer, which comes with extremely low survival rates.
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • Further survival follow up is required to inform our next steps in pancreatic cancer," said Roger Dansey, M.D., Chief Medical Officer at Seagen.
  • "We are continuing to advance the ongoing phase 2 trial of SEA-CD40 in melanoma and in non-small cell lung cancer."